Tafamidis
| CAS No. | 594839-88-0 | Cat. No. | BCP29089 |
| Name | Tafamidis | ||
| Synonyms | Fx-1006; Fx1006; Fx 1006; PF-06291826; PF06291826; PF 06291826; | ||
| Formula | C14H7Cl2NO3 | M. Wt | 308.12 |
| Description | Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein. | ||
| Pathways | Others Pathway | ||
| Targets | Others | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.